Administer effective prophylactic treatment strategies for dermatologic toxicities associated with EGFR inhibitors in oncology patients receiving therapy with these agents
Employ optimal management strategies for long-term treatment-related adverse events associated with EGFR inhibitors
Identify and treat dermatologic infections associated with EGFR inhibitor therapy in oncology patients receiving treatment with these agents
Counsel patients on the anticipated dermatologic toxicities associated with EGFR inhibitors and optimal prophylactic and management strategies
Other Guidelines and Tools
MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) (1.1MB ppt)
Developed by the MASCC Skin Toxicity Study Group in 2008.
Caring for your skin, hair and nails on "Targeted Therapies" - Download this brochure for patients with EGFRI side effects.
Mission
The mission of the MASCC Skin Toxicity Study Group is to develop research and management strategies for skin conditions due to cancer or anticancer drugs. Skin reactions are frequent in those affected by cancer. They can reduce quality of life and require modifications in lifesaving antineoplastic therapy. This interdisciplinary Study Group aims to raise awareness of dermatological conditions in cancer patients and take a leadership role in the emerging field of cancer-related skin toxicities management.
Objectives
The objectives of the Skin Toxicity Study Group include the following:
To identify new targets for the treatment of skin reactions
To establish guidelines for management
To contribute to patients' knowledge of reactions and their care.
Key efforts are directed toward the identification of phenotypes and treatment regimens with a higher risk, as well as preventive measures and early intervention as standards of care. This Study Group also serves as a resource for multicenter clinical trials and translational studies.